About Biophytis SA American Depositary Share
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France. Address: Sorbonne University, Paris, France, 75005
Biophytis SA American Depositary Share News and around…
Latest news about Biophytis SA American Depositary Share (BPTS) common stock and company :
Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's ...
Gainers Sesen Bio (NASDAQ:SESN) stock increased by 29.2% to $1.3 during Wednesday's regular session. Trading volume ...
Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that the Company’s previously iss
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will host a virtual key opinion leader (KOL) event on October
PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the issuance of 240 Bonds Redeemable in Cash and New and Exist
Figure 1 Effect of Sarconeos (BIO101) on the 400 MWT gait speed in the FAS and PP populations Figure 2 Effect of Sarconeos (BIO101) on the 400MWT gait speed in sub-population with higher risk of mobility disability (chair stand subscore ≤2) Figure 3 Adverse Events, Serious Adverse Events and Treatment Emergent Adverse Events in the Placebo, 175 mg bid and 350 mg bid groups in the SARA-INT study Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the
Gainers OptimizeRx (NASDAQ:OPRX) stock increased by 12.12% to $84.05 during Thursday's pre-market session. The ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Gainers Superior Drilling Products, Inc. (NYSE: SDPI) rose 58.7% to $1.73 in pre-market trading after jumping over 23% on ...
PARIS and CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will present full results from the SARA-INT Phase 2 trial of
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
The Data Monitoring Committee (DMC) has recommendedBiophytis SA(NASDAQ: BPTS)to continue patient ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market ...
Wednesday's morning session saw 58 companies set new 52-week lows. Noteworthy Mentions: The company ...
Gainers Exicure (NASDAQ:XCUR) stock moved upwards by 35.55% to $1.83 during Monday's pre-market session. The ...
Biophytis SA(NASDAQ: BPTS)has announced top-line resultsof the SARA-INT phase 2 clinical study with Sarconeos ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Biophytis SA American Depositary Share (BPTS) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
